Evaluating effect of teriflunomide on cortical atrophy in a subgroup analysis of patients defined by baseline MRI activity in the Phase 3 TOPIC study

被引：0
|
作者：
Zivadinov, R. [1 ]
Dwyer, M. G. [1 ]
Carl, E. [1 ]
Thangavelu, K. [2 ]
Cavalier, S. [2 ]
Bergsland, N. [1 ]
机构：
[1] Univ Buffalo, Buffalo, NY USA
[2] Sanofi Genzyme, Cambridge, MA USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2017年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PR2092
引用
收藏
页码：580 / 580
页数：1
相关论文
共 50 条
  • [11] Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study
    Qiu Wei
    Huang De-Hui
    Hou Shi-Fang
    Zhang Mei-Ni
    Jin Tao
    Dong Hui-Qing
    Peng Hua
    Zhang Chao-Dong
    Zhao Gang
    Huang Yi-Ning
    Zhou Dong
    Wu Wei-Ping
    Wang Bao-Jun
    Li Ji-Mei
    Zhang Xing-Hu
    Cheng Yan
    Li Hai-Feng
    Li Ling
    Lu Chuan-Zhen
    Zhang Xu
    Bu Bi-Tao
    Dong Wan-Li
    Fan Dong-Sheng
    Hu Xue-Qiang
    Xu Xian-Hao
    中华医学杂志英文版, 2018, 131 (23) : 2776 - 2784
  • [12] Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study
    Qiu, Wei
    Huang, De-Hui
    Hou, Shi-Fang
    Zhang, Mei-Ni
    Jin, Tao
    Dong, Hui-Qing
    Peng, Hua
    Zhang, Chao-Dong
    Zhao, Gang
    Huang, Yi-Ning
    Zhou, Dong
    Wu, Wei-Ping
    Wang, Bao-Jun
    Li, Ji-Mei
    Zhang, Xing-Hu
    Cheng, Yan
    Li, Hai-Feng
    Li, Ling
    Lu, Chuan-Zhen
    Zhang, Xu
    Bu, Bi-Tao
    Dong, Wan-Li
    Fan, Dong-Sheng
    Hu, Xue-Qiang
    Xu, Xian-Hao
    CHINESE MEDICAL JOURNAL, 2018, 131 (23) : 2776 - 2784
  • [13] Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study
    Miller, Aaron E.
    Xu, Xianhao
    Macdonell, Richard
    Vucic, Steve
    Truffinet, Philippe
    Benamor, Myriam
    Thangavelu, Karthinathan
    Freedman, Mark S.
    JOURNAL OF CLINICAL NEUROSCIENCE, 2019, 59 : 229 - 231
  • [14] Evaluating the effect of teriflunomide in subgroups defined by prior treatment: pooled analyses of the phase 3 TEMSO and TOWER studies
    Freedman, M. S.
    Dukovic, D.
    Benamor, M.
    Truffinet, P.
    Kappos, L.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 87 - 87
  • [15] Effect of teriflunomide in subgroups defined by prior treatment: pooled analysis of the phase 3 TEMSO, TOWER, and TENERE studies
    Comi, G.
    Freedman, M. S.
    Meca-Lallana, J.
    Vermersch, P.
    Kim, B.
    Parajeles, A.
    Edwards, K.
    Gold, R.
    Overell, J.
    Korideck, H.
    Chavin, J.
    Poole, E.
    Coyle, P.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 682 - 682
  • [16] Effect of teriflunomide on mri lesion activity across age groups in patients with relapsing multiple sclerosis from the temso study
    Oh, J.
    Wuerfel, J.
    Khatri, B.
    Miller, A.
    Inshasi, J.
    Saiz, A.
    Lublin, A.
    Poole, E.
    Sprenger, T.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 216 - 216
  • [17] Long-Term Effect of Teriflunomide in Subgroups Defined by Prior Treatment: Pooled Analysis of the Phase 2 Study and Phase 3 TEMSO, TOWER, and TENERE Core and Extension Studies
    Comi, Giancarlo
    Freedman, Mark
    Meca-Lallana, Jose
    Vermersch, Patrick
    Kim, Byoung Joon
    Parajeles, Alexander
    Edwards, Keith
    Gold, Ralf
    Overell, James
    Korideck, Houari
    Chavin, Jeffrey
    Poole, Elizabeth
    Coyle, Patricia
    NEUROLOGY, 2019, 92 (15)
  • [18] Effect of Siponimod on Cognition in Patients with Secondary Progressive Multiple Sclerosis (SPMS): Phase 3 EXPAND Study Subgroup Analysis
    Benedict, Ralph
    Fox, Robert
    Tomic, Davorka
    Cree, Bruce
    Vermersch, Patrick
    Giovannoni, Gavin
    Bar-Or, Amit
    Gold, Ralf
    Ritter, Shannon
    Karlsson, Goeril
    Wolf, Christian
    Kappos, Ludwig
    NEUROLOGY, 2019, 92 (15)
  • [19] A SUBGROUP ANALYSIS OF LOW DISEASE ACTIVITY AND REMISSION FROM PHASE 3 STUDY OF FILGOTINIB IN PATIENTS WITH INADEQUATE RESPONSE TO BIOLOGIC DMARDS
    Gottenberg, J. E.
    Buch, M. H.
    Caporali, R.
    Wright, G. C.
    Takeuchi, T.
    Kalunian, K.
    Pechonkina, A.
    Guo, Y.
    Rao, S.
    Tan, Y.
    Besuyen, R.
    Genovese, M. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 322 - 323
  • [20] CARFILZOMIB AND DEXAMETHASONE VS BORTEZOMIB AND DEXAMETHASONE: SUBGROUP ANALYSIS OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA BY BASELINE CYTOGENETIC RISK STATUS (PHASE 3 ENDEAVOR STUDY)
    Goldschmidt, H.
    Chng, W. J.
    Dimopoulos, M. A.
    Moreau, P.
    Joshua, D.
    Palumbo, A.
    Facon, T.
    Ludwig, H.
    Pour, L.
    Niesvizky, R.
    Oriol, A.
    Rosinol, L.
    Suvorov, A.
    Gaidano, G.
    Pika, T.
    Weisel, K.
    Goranova-Marinova, V.
    Gillenwater, H. H.
    Mohamed, N.
    Feng, S.
    Hajek, R.
    HAEMATOLOGICA, 2016, 101 : 523 - 523
12345